Fate Therapeutics (FATE) Invested Capital (2016 - 2025)
Fate Therapeutics' Invested Capital history spans 14 years, with the latest figure at $207.2 million for Q4 2025.
- For Q4 2025, Invested Capital fell 35.0% year-over-year to $207.2 million; the TTM value through Dec 2025 reached $207.2 million, down 35.0%, while the annual FY2025 figure was $207.2 million, 35.0% down from the prior year.
- Invested Capital reached $207.2 million in Q4 2025 per FATE's latest filing, down from $234.1 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $790.1 million in Q1 2021 to a low of $207.2 million in Q4 2025.
- Average Invested Capital over 5 years is $467.4 million, with a median of $431.9 million recorded in 2023.
- Peak YoY movement for Invested Capital: soared 260.42% in 2021, then crashed 35.4% in 2025.
- A 5-year view of Invested Capital shows it stood at $678.8 million in 2021, then decreased by 28.71% to $483.9 million in 2022, then dropped by 23.87% to $368.4 million in 2023, then decreased by 13.49% to $318.7 million in 2024, then crashed by 35.0% to $207.2 million in 2025.
- Per Business Quant, the three most recent readings for FATE's Invested Capital are $207.2 million (Q4 2025), $234.1 million (Q3 2025), and $261.4 million (Q2 2025).